ECARX (ECX) Competitors

Enfusion (NYSE:ENFN) and ECARX (NASDAQ:ECX) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

Does the media favor ENFN or ECX?

In the previous week, Enfusion had 2 more articles in the media than ECARX. MarketBeat recorded 7 mentions for Enfusion and 5 mentions for ECARX. Enfusion's average media sentiment score of 1.31 beat ECARX's score of 0.57 indicating that Enfusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enfusion	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ECARX	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ENFN or ECX?

Enfusion received 8 more outperform votes than ECARX when rated by MarketBeat users. However, 100.00% of users gave ECARX an outperform vote while only 19.61% of users gave Enfusion an outperform vote.

Company	Underperform	Outperform
Enfusion	Outperform Votes 10 19.61%	Underperform Votes 41 80.39%
ECARX	Outperform Votes 2 100.00%	Underperform Votes No Votes

Do insiders and institutionals believe in ENFN or ECX?

81.1% of Enfusion shares are owned by institutional investors. 36.4% of Enfusion shares are owned by company insiders. Comparatively, 20.0% of ECARX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more volatility & risk, ENFN or ECX?

Enfusion has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, ECARX has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Do analysts rate ENFN or ECX?

Enfusion currently has a consensus target price of $11.83, indicating a potential upside of 9.37%. ECARX has a consensus target price of $3.20, indicating a potential upside of 237.55%. Given ECARX's stronger consensus rating and higher possible upside, analysts plainly believe ECARX is more favorable than Enfusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enfusion	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
ECARX	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, ENFN or ECX?

Enfusion has higher earnings, but lower revenue than ECARX. ECARX is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enfusion	$201.61M	6.92	$6.03M	$0.03	360.67
ECARX	$5.56B	0.06	-$132.42M	-$0.39	-2.43

Is ENFN or ECX more profitable?

Enfusion has a net margin of 1.70% compared to ECARX's net margin of -22.01%. Enfusion's return on equity of 6.67% beat ECARX's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enfusion	1.70%	6.67%	4.86%
ECARX	-22.01%	N/A	-30.30%

Summary

Enfusion beats ECARX on 14 of the 18 factors compared between the two stocks.